Navigation Links
The Ludwig Institute for Cancer Research announces launch of iTeos Therapeutics SA

NEW YORK, NY, May 3, 2012 The Ludwig Institute for Cancer Research (LICR) announced today the launch of a private biotechnology enterprise, iTeos Therapeutics SA, to develop a novel pre-clinical pipeline of immunomodulators to stimulate the immune system's ability to attack cancer. Founded by LICR with the de Duve Institute at the Universit catholique de Louvain (UCL), iTeos is led by a team experienced in tumor immunology, immunotherapy, drug discovery, business development and entrepreneurship. iTeos is the ninth new company formed based on innovative cancer research discoveries licensed from LICR.

The field of cancer immunotherapy has come to the fore in the last two years with the approval of drugs and vaccines that harness the power of the immune system to treat cancer patients more safely, efficiently and effectively. However, therapeutic uses of these treatments can be limited as the tumors often develop mechanisms that enable them to escape the immune system. iTeos brings together world-class expertise in tumor immunology and immunotherapy, with a focus on developing small molecule immunomodulators to counteract cancer immunosuppression.

"Immunotherapy boosting the body's natural immune system to fight cancerous tumors is the next frontier in life-extending cancer treatment," said Benot Van den Eynde, M.D., Ph.D., Brussels Branch Director at LICR, UCL Professor and co-founder of iTeos. "Effective immunotherapy treatments enable the body's immune system to 're-engage' in destroying tumor cells, thereby potentially creating better patient outcomes with fewer side effects when compared to conventional cancer treatments."

"iTeos' mission is to translate pioneering scientific discovery into meaningful treatments for people living with cancer," said iTeos co-founder and CEO Michel Detheux, Ph.D. "We now know that combination treatments are likely to be more effective than single therapies in controlling and eventually eliminating cancer. iTeos will pursue this approach by combining existing vaccines with new immunodulatory compounds based on research that has just emerged from the Ludwig Institute."

iTeos' initial goals are to reach a proof of concept in humans by completing a Phase I/IIa study for the first compound program and to submit an Investigational New Drug application for a second candidate in four years.

Ludwig and UCL scientists, led by Dr. Van den Eynde, recently made the breakthrough discovery of the potential role of TDO in immunotherapy. TDO is a critical enzyme that is produced by a significant number of human tumors. In research published in the 30 January 2012 issue of Proceedings of the National Academy of Sciences, Dr. Van den Eynde's team showed that blocking TDO with a novel inhibitor promotes tumor rejection in mice. This team was also responsible for recognizing the role that a similar enzyme, IDO, plays in tumor growth. TDO and IDO inhibitors are now in preclinical development at iTeos.

"Preclinical studies suggest that TDO inhibition may be beneficial in treating bladder, liver and melanoma skin cancers. Suppressing IDO may help to positively impact ovarian, prostate, pancreatic and colorectal cancer treatment among others," said Dr. Detheux. "iTeos' focus is to bring these and other truly novel compounds to become part of the standard of care for cancer treatment."

"LICR has the expertise to conduct and administer its own early phase clinical trials as part of its technology development process," said Jonathan Skipper, Ph.D., Executive Director of Technology Development at LICR. "Spin-off companies, such as iTeos, have access to this infrastructure so that candidate therapeutics can be further tested. This allows LICR to continue to have input into the development of its discoveries and, more importantly, ensure promising new therapies will eventually reach patients."

Strong third-party endorsement is behind iTeos, including early funding by the Belgian Walloon Government. In fact, the creation of the spin-off was made possible by the grant from a Walloon FIRST spin-off mandate. Then, in December 2011, the Walloon Government awarded iTeos a research grant for $8M (6M). This support builds upon the progress of an earlier government program, the Biowin Pole of "Plan Marshall," aimed at the development of small molecule inhibitors.

Contact: Rachel Steinhardt
Ludwig Institute for Cancer Research

Related medicine news :

1. Professor Cesare Montecucco to receive the 2011 Paul Ehrlich and Ludwig Darmstaedter Prize
2. Bascom Palmer Eye Institute announces breakthrough for degenerative vision disorder
3. David H. Koch donates $10 million to Mount Sinais Jaffe Food Allergy Institute
4. National institute launched to help businesses grow with Asian consumers
5. Regenstrief Institute investigator recognized as a Top New Geriatrics Investigator
6. A.J. Drexel Autism Institute receives $1.5 million from the Charles and Barbara Close Foundation
7. American College of Cardiology honors 2 Cedars-Sinai Heart Institute physicians
8. Ragon Institute study finds HIV-specific CD4 cells that control viral levels
9. UC Davis MIND Institute researchers to present on autism at AAAS Annual Meeting in Vancouver
10. Professor from Karolinska Institutet now international educator
11. University Hospitals receives $5 million gift for Eye Institute
Post Your Comments:
(Date:11/30/2015)... MN (PRWEB) , ... November 30, 2015 , ... ... at . The directory is specialized and only includes chiropractic clinics ... to find a competent and trustworthy alternative health practitioner when back pain sets ...
(Date:11/30/2015)... ... November 30, 2015 , ... In an effort ... the Word of Life Christian Church of Flint, MI, hosted a family-oriented evening ... 1.25 ton pile of candy dubbed “Candy Mountain”. , A Forever Recovery, a ...
(Date:11/30/2015)... ... November 30, 2015 , ... During ... fundraising campaign to raise funds for its research, education, support, and advocacy efforts. ... organization’s annual funding. , The Mesothelioma Applied Research Foundation, which also goes by ...
(Date:11/30/2015)... Dallas, TX (PRWEB) , ... November 30, 2015 ... ... its primary Catalyst continuing education course in Dallas, TX, on January 29 and ... are looking to improve the functions of their practices, to learn how to ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... chart and ingredient list of its hemorrhoid ointment to its website. , “Our ... relief for people suffering from hemorrhoids. Adding the comparison chart and ingredient list ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... and ST. LOUIS , Nov. ... (NASDAQ: ESRX ) today announced an early renewal ... which began in 1999, will now extend through at ... --> After evaluating pharmacy benefit manager capabilities during ... Express Scripts continues to offer the best health plan ...
(Date:11/30/2015)... Nov. 30, 2015 iCAD, Inc. (Nasdaq: ... feature its latest solutions for advanced image analysis ... cancer at the Radiological Society of North American ... from November 29 to December 4, ... including iReveal®, an automated breast density assessment solution, ...
(Date:11/30/2015)... 30, 2015 NHS Supply Chain has ... machines from Varian Medical Systems (NYSE: VAR ... replace older machines and institute modern radiotherapy and ... hospitals. The order, placed in September, also includes ... Varian,s RapidArc® and Eclipse™ software systems.    ...
Breaking Medicine Technology: